top of page
© Hairuhusiwi kukopi bila kibali cha ULYCLINIC

Prostate cancer


Usually occurs in men over 50 years and is most often asymptomatic. Systemic symptoms, i.e. weight loss, bone pain, etc. occurs in 20% of patients. Obstructive voiding symptoms and urinary retention are uncommon.

Risk factors

Signs and Symptoms

Diagnostic criteria

• The prostate gland is hard and may be nodular on digital rectal examination and/or PSA elevation
• Verification of prostate cancer is by prostate core biopsy
• As the axial skeleton is the most common site of metastases, patients may present with back pain or pathological fractures.
• Lymph node metastases can lead to lower limb lymphoedema.
• Serum prostate specific antigen (PSA) is generally elevated and may be markedly so in metastatic disease.
• Non-pharmacological treatment
• Wathful waiting- low risk patients with short life expectancy
• Active surveillance-lowest risk of cancer progression and more than 10 years life expectancy
• Radical prostatectomy- patients with localized cancer and life expectancy more than 10 years
• Surgical Androgen deprivation therapy (bilateral orchidectomy) for advanced prostate cancer



  • Pharmacological

    Medical androgen Deprivation Therapy is offered in patients with advanced disease, PSA levels more than 50 ng/ml, poorly differentiated tumour and in those who cannot receive any form of local treatment.

    Luitenising hormone releasing hormone (LHRH) Agonists

    • Inj Goserelin 3.6 mg subcutaneous every weeks or 10.8mg every 12 weeks


    • Bicalutamide (PO) 50–150mg once daily

    Castrate resistant prostate cancer

    • Docetaxel 75mg/m2 every 3 weeks


    All patients with suspected cancer (For more detail refer to the Malignant diseases section)
  • Non-pharmacological


Updated on,

23 Novemba 2020 12:24:35


I'm a paragraph. I'm connected to your collection through a dataset. Click Preview to see my content. To update me, go to the Data Manager.

bottom of page